111-19-3Relevant articles and documents
-
Gerlach,H.,Huber,E.
, p. 2027 - 2044 (1968)
-
Electrochemical and nonelectrochemical analyses of cardo polyesters at the metal/0.5?M H2SO4 interface for corrosion protection
Unnisa, Chan Basha Nusrath,Chitra, Subramanian,Nirmala Devi, Gowraraju,Kiruthika, Ayyasamy,Roopan, Selvaraj Mohana,Hemapriya, Venkatesan,Chung, Ill-Min,Kim, Seung-Hyun,Prabakaran, Mayakrishnan
, p. 5425 - 5449 (2019)
With the aim of decreasing the corrosion of metal specimens, two polyesters, namely 4-(1-(4-methoxyphenyl)cyclohexyl)phenyl 3-oxobutanoate (MPOB) and 4-(1-(4-methoxyphenyl)cyclohexyl)phenyl 10-oxoundecanoate (MPOU), were synthesized and utilized as corrosion inhibitors. The synthesized polyesters were characterized by Fourier-transform infrared (FT-IR) and nuclear magnetic resonance spectral analyses, followed by thermogravimetric and differential scanning calorimetry analyses. The protective effect of the polyesters on mild-steel specimens in 0.5?M H2SO4 medium was evaluated by nonelectrochemical and electrochemical methods. Gravimetric measurements revealed a decreased corrosion rate with increasing concentration of the inhibitors, reaching a maximum inhibition efficiency of 79.88% for MPOB and 92.98% for MPOU at 1000?ppm concentration at room temperature. The obtained experimental data were best fit by the Langmuir adsorption isotherm, suggesting monolayer adsorption. Thermodynamic parameters supported a physisorption mechanism. Electrochemical impedance spectroscopy showed increased charge-transfer resistance (Rct), in turn decreasing the double-layer capacitance and thereby favoring good inhibition of corrosion of mild steel. Mixed-type inhibition was revealed by potentiodynamic polarization analysis, suppressing anodic metal dissolution and cathodic hydrogen evolution. The mode of adsorption of the inhibitors on the mild-steel surface was additionally evaluated by morphological study using FT-IR and atomic force microscopy (AFM) analyses.
Synthesis and bio-evaluation of Tc-99 m-labeled fatty acid derivatives for myocardial metabolism imaging
Liu, Jianping,Xue, Qianqian,Wang, Huan,Wang, Hang,Wang, Dawei,Fang, Yu,Zhang, Huabei
, p. 596 - 604 (2016)
11C, 18F and 123I fatty acids are used for myocardial imaging, and 99mTc-labeled fatty acids are more desirable substitutes than other radiolabeled fatty acids. In the work reported, [99mTc]-CpTT-10-oxo-FPA (1c), [99mTc]-CpTT-12-oxo-FPA (2c), [99mTc]-CpTT-14-oxo-FPA (3c) and [99mTc]-CpTT-16-oxo-FPA (4c) were prepared with 60.76–70.92% of radiochemical yield and purity of more than 95%. These radiotracers (1c, 2c, 3c, 4c) were chemically stable when incubated in Sprague Dawley rat serum for 3 h at 37 °C. Tissue distribution studies in female mice indicated that 2c had high initial heart uptake (8.84%ID g?1 at 1 min post-injection) and 4c had long retention in the heart (1.45%ID g?1 at 30 min post-injection). Metabolite analysis showed 4c could be metabolized to 5c via β-oxidation with loss of two ?CH2? in the myocardium, the radiometabolite being excreted via urine. However, low heart uptake suggested that 4c cannot be used as a diagnostic imaging agent. Copyright
LIPID PRODRUGS OF GLUCOCORTICOIDS AND USES THEREOF
-
Paragraph 00404; 00405, (2020/09/12)
The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF
-
Paragraph 00411-00412, (2020/09/12)
The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.